ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: PR Newswire
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold. The transaction is valued at approximately $739 million and is expected to close in the third quarter of 2026.If you are a stockholder of XOMA Royalty Corporation and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/xoma/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).Rowley Law PLLC represents stockholders nationwide in class actions and
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator GlobeNewswire
- Ligand to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswire
- Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.MarketBeat
- Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 4/27/26 - Form DEFA14A
- 4/27/26 - Form 8-K
- 4/21/26 - Form ARS
- LGND's page on the SEC website